Guidance for laboratories performing molecular pathology for cancer patients. - Wikidata - wikimedia - TriplyDB

Guidance for laboratories performing molecular pathology for cancer patients.

Guidance for laboratories performing molecular pathology for cancer patients.

http://www.wikidata.org/entity/Q34431280

about

Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients Evolving health care through personal genomics.Good Laboratory Standards for Clinical Next-Generation Sequencing Cancer Panel Tests.A reliable method for the detection of BRCA1 and BRCA2 mutations in fixed tumour tissue utilising multiplex PCR-based targeted next generation sequencing KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics Pitfalls of improperly procured adjacent non-neoplastic tissue for somatic mutation analysis using next-generation sequencing.Molecular chess? Hallmarks of anti-cancer drug resistance Validation of an NGS mutation detection panel for melanoma.RAS testing in metastatic colorectal cancer: advances in Europe Longitudinal molecular characterization of endoscopic specimens from colorectal lesions.Diagnostic RAS mutation analysis by polymerase chain reaction (PCR).Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.Endorsing good quality assurance practices in molecular pathology: risks and recommendations for diagnostic laboratories and external quality assessment providers.Quality Assessment of Reporting Performance for EGFR Molecular Diagnosis in Non-Small Cell Lung Cancer.Considerations for standardizing predictive molecular pathology for cancer prognosis.Massive parallel sequencing of solid tumours - challenges and opportunities for pathologists.PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation.The ins and outs of molecular pathology reporting.Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL.The homogeneous mutation status of a 22 gene panel justifies the use of serial sections of colorectal cancer tissue for external quality assessment.The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review.Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers' survey.Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy.Next-Generation Sequencing in Diagnostic Pathology.Advances in liquid biopsy on-chip for cancer management: Technologies, biomarkers, and clinical analysis.Impact of genomics on the surgical management of melanoma.Utilizing the Luminex Magnetic Bead-Based Suspension Array for Rapid Multiplexed Phosphoprotein Quantification.Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients.Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns.A stitch in time saves nine: external quality assessment rounds demonstrate improved quality of biomarker analysis in lung cancer.Practical issues of biomarker-assisted targeted therapy in precision medicine and immuno-oncology era.Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?High-resolution melting analysis coupled with next-generation sequencing as a simple tool for the identification of a novel somatic BRCA2 variant: a case report.Comparative proteomics reveals a diagnostic signature for pulmonary head-and-neck cancer metastasis

P2860

Q26776394-EEDB5BC4-EAF0-4B6E-8A98-0CC88B21F85C Q28075719-4785A8F2-3C98-4A0B-8E30-9D18AE4D480C Q28603931-5483D360-A134-44B7-8799-CE929D50C052 Q30398030-B5191624-AA34-46A2-96A5-6347512BFEC9 Q33729699-64AEBFF2-DC53-4CC6-B297-CA457084F323 Q35336961-A4160E0E-2C68-47F3-AED4-EA66D588039B Q35760814-D2E276BB-0B69-4551-B51A-495AFF5B4284 Q35798726-6F467D8D-5DED-485B-8391-A0C46C3EF75D Q36166879-A5FDD259-3629-45E4-A6DE-6AE734DB10DE Q36240941-8A6CAFF1-47B6-43FC-BD85-1BD48BBA3F9F Q36287755-2CF30317-73A6-4A3F-A4CC-C082F0ECC317 Q36795904-519AE30E-D7D0-45AE-BA41-B4964D79DB67 Q36919467-7FDC0EED-80CB-4822-9FDC-BAA4CA87C7A4 Q37000019-377FA116-F072-4986-94CF-0B286B1EC6B4 Q37417271-CE1F8003-647A-443F-844A-022632C24453 Q38573698-071BF53B-EE87-4718-B575-140E3DF0AE48 Q38658503-D6FDC6FA-AB8B-48DB-B2C1-C51E77E54F18 Q38789496-92B0C7A2-5908-4A2C-82D7-F686F2129ABC Q38828314-557E19C4-82AB-419F-8734-559D2ED7A84E Q38838347-C08D166E-8F99-48BF-8196-F6E09AE5051E Q38875985-3D11C8EC-1B7B-42B7-94D8-AF0313A2143E Q38966415-84DA4A0D-AE5A-4C03-826A-3DFC8853C2D5 Q40865086-11FC2E43-BF5B-4103-B47B-743EAA12FA5F Q42643973-AA690B82-D1A5-41A7-B50C-D4CB240DC4DF Q47122740-24177A8A-9289-423E-B113-6944D915E9AA Q47273844-08853DBA-4DD1-402C-9D77-759ADBF905D4 Q47609024-35FEAB72-BDC7-4AB6-B496-C877076E8A08 Q49502117-ECB9CC46-DF2B-4A88-AC6B-ABE296C46597 Q50010320-B16917C2-206D-4127-BBD4-63CB9DB8B78C Q50878626-0D63D2C7-9923-4B87-9780-886EC51FBBCB Q52332839-A45FD097-7931-45FE-9F74-55BD2841782E Q53721511-AFCCACF7-E37E-410B-BE14-3E2D43C904F2 Q55016872-5B50D7A8-7B27-4292-8DF8-712B8BD93E83 Q55249373-A55FBEAC-DCB2-48F5-9529-5AB597CB6B16 Q55318335-32F80148-1B3F-446C-89FB-38AEC1B808B5 Q55396915-2D85437D-97B9-4B68-8466-C96F5D5CEA07 Q58789206-D161FEB2-6292-4628-B28D-0F9DB5FEDBEA

P2860

Guidance for laboratories performing molecular pathology for cancer patients.

http://www.wikidata.org/entity/Q34431280

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Guidance for laboratories performing molecular pathology for cancer patients.

@ast

Guidance for laboratories performing molecular pathology for cancer patients.

@en

Guidance for laboratories performing molecular pathology for cancer patients.

@nl

type

label

Guidance for laboratories performing molecular pathology for cancer patients.

@ast

Guidance for laboratories performing molecular pathology for cancer patients.

@en

Guidance for laboratories performing molecular pathology for cancer patients.

@nl

prefLabel

Guidance for laboratories performing molecular pathology for cancer patients.

@ast

Guidance for laboratories performing molecular pathology for cancer patients.

@en

Guidance for laboratories performing molecular pathology for cancer patients.

@nl

P1433

Q34431280-198421B5-25CE-4C1C-ABB6-65CEC2F1F598

P1476

Q34431280-8DD012BA-669C-4892-9036-5C43E23EAC66

P2093

Q34431280-0BC29A3D-270E-4925-8E75-87445E1A8244

Q34431280-40F5F9FE-E123-48BC-B037-8D2C0A5D69E8

Q34431280-42016A3A-846D-49C3-A739-170F0B26F1AC

Q34431280-52E8021B-A140-4196-ADF7-E6498431B821

Q34431280-626D2FD7-3236-4D8E-AE54-9D0E807CAE60

Q34431280-692AAE16-E78C-4ACC-807B-09EB105AF766

Q34431280-7FF428A4-5468-4372-B7A5-CA5277F860CE

Q34431280-9D9B0905-86E8-45C1-8654-7EB908C7FF6E

Q34431280-B49CCD9D-172B-46A0-BD83-E2E8628A16FE

Q34431280-B50938DC-AE81-45B2-82C2-143B3E242FAD

P275

Q34431280-95B8421D-A27B-4E1A-869F-6694FC3CD2D1

P2860

Q34431280-006A06AC-5DCF-4AE4-922C-24B1EFDB9346

Q34431280-05804D1E-2552-43B5-AF52-B95F2C40C4E9

Q34431280-0E132192-E67E-45A0-88B8-38F40C87B18A

Q34431280-19D1612C-6BAA-4C5C-BA5D-67A5DD58A74D

Q34431280-1D4F8F53-12B5-4A9C-8FD4-7CDDE5C3037E

Q34431280-28755E2F-C41A-4296-B68D-C20189EAB1B0

Q34431280-31533747-5F0D-4F49-BC65-E600094E9329

Q34431280-387430A4-240B-4ADE-97B3-7134E014AD51

Q34431280-3E2BE8F5-129A-400C-AAE5-0E41C3698061

Q34431280-40E99CE4-3FA9-43BF-A969-EDED65B13BBA

P304

Q34431280-A72D507B-47FE-413F-BB6F-38956D38EEC2

P31

Q34431280-72B61781-3AFB-4EF9-866F-AF317B7C08E9

Q34431280-F7EB74B5-DED1-4C12-8922-60FA449C55C6

P356

Q34431280-120B1788-2768-41DE-B87A-C4FE6425B7C6

P407

Q34431280-6703FA39-8E91-4082-95E8-D308B64FF820

P433

Q34431280-9E81D0B1-3367-494F-AFF4-BB41A1DE737D

P478

Q34431280-DF512A87-F6AA-4576-9409-56CD85E3B368

P50

Q34431280-13AC7516-6D58-4961-9997-27CB2B9EA30E

Q34431280-2307BEA7-3047-47E3-8A47-686D509B5F09

Q34431280-F774450E-44DF-45EA-94C2-537DA4120674

P5008

Q34431280-3F3D0810-EC3A-4D60-B634-E5F740C782C3

P577

Q34431280-26F769A3-AB58-4B9B-88C3-D1DBADEDB2F5

Q34431280-DA82BCE6-6FF1-4BF9-910F-58E8782407CD

P5875

Q34431280-0C1FF757-1D58-43CA-8F48-8011B5C6B311

P698

Q34431280-6B2C31AD-C962-4279-86C9-EF27434DA502

P921

Q34431280-0C7B6040-F823-4616-9253-8D31C56C3D31

Q34431280-326E7855-A160-4947-A11B-5BEB4D98A6FB

Q34431280-3B10405B-5D67-43FB-93FA-CD8123307EBF

Q34431280-BA7C9697-B36F-4ACB-BB87-1D02072D7598

Q34431280-fb712f46-53e0-4436-9ab8-71f36157779c

P932

Q34431280-3A01CDE1-6D44-4338-ABB3-9F1CAFB1E889

P356

JCLINPATH-2014-202404

P1433

Journal of Clinical Pathology

P1476

Guidance for laboratories performing molecular pathology for cancer patients.

@en

P2093

Anders Edsjö

http://www.w3.org/2001/XMLSchema#string

Ed Schuuring

http://www.w3.org/2001/XMLSchema#string

Elisabeth Dequeker

http://www.w3.org/2001/XMLSchema#string

Erik Thunnissen

http://www.w3.org/2001/XMLSchema#string

Etienne Rouleau

http://www.w3.org/2001/XMLSchema#string

European Society of Pathology Task Force on Quality Assurance in Molecular Pathology

http://www.w3.org/2001/XMLSchema#string

Francesc Solé

http://www.w3.org/2001/XMLSchema#string

Ian A Cree

http://www.w3.org/2001/XMLSchema#string

J Han Van Krieken

http://www.w3.org/2001/XMLSchema#string

Marjolijn J L Ligtenberg

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Cancer cell adaptation to chemotherapy.

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

The genetic basis for cancer treatment decisions

KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

Detection of circulating tumor DNA in early- and late-stage human malignancies

Opening the archives for state of the art tumour genetic research: sample processing for array-CGH using decalcified, formalin-fixed, paraffin-embedded tissue-derived DNA samples

Formalin fixation at low temperature better preserves nucleic acid integrity.

Multicentre validation study of nucleic acids extraction from FFPE tissues.

P304

923-931

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JCLINPATH-2014-202404

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P50

Nicola Normanno

P5008

P577

2014-07-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2014-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264633301

http://www.w3.org/2001/XMLSchema#string

P698

25012948

http://www.w3.org/2001/XMLSchema#string

P921

preventive health services

tumor biomarkers

biomedical investigative technique

P932

4215286

http://www.w3.org/2001/XMLSchema#string